Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas, Genentech, Servier Pharmaceuticals LLC.

2021 SOHO ISS: Medical Crossfire®: How Can We Leverage Emerging Data to Optimize Outcomes Across Lines of Care in AML?

Release Date: October 29, 2021
Expiration Date: October 29, 2022

Activity Overview

Acute myeloid leukemia (AML), a heterogenous hematologic malignancy, is the most common form of acute leukemia among adults. Until recently, relatively few major treatment breakthroughs had occurred for patients with AML. Treatment approaches relied almost exclusively on chemotherapy and, in some cases, hematopoietic stem cell transplantation (HSCT). However, rapidly emerging therapy options have dramatically improved outcomes in patients with both newly-diagnosed, as well as relapsed/refractory AML. In this program, expert hematologists will review clinical data on biomarkers that play a role in predicting the prognosis of patients with AML and selecting therapy, and on available and emerging therapies across the spectrum of the disease.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astellas, Genentech, Servier Pharmaceuticals LLC.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with acute myeloid leukemia (AML). Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with AML are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Identify biomarkers and appropriate testing strategies for prognosis, risk stratification, and treatment planning in AML.
Evaluate clinical trial data for current- and emerging therapeutic strategies across lines of care in AML.
Integrate evidence-based strategies, including consensus guidelines and emerging treatment options, into the evolving treatment paradigm for patients with AML.
Outline strategies to monitor, mitigate, and manage adverse events associated with treatments for AML.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Faculty

Gail J. Roboz, M.D.
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

Disclosures: Grant/Research Support: Cellectis; Janssen; Consultancy or Advisory Board or Data and Safety Monitoring Committee: AbbVie; Actinium; Agios; Amgen; Astex; Astellas; AstraZeneca; Bayer; Blueprint Medicines; Bristol Myers Squibb; Celgene; Daiichi; Sankyo; Glaxo SmithKline; Helsinn; Janssen; Jasper Therapeutics; Jazz; MEI Pharma – IDMC Chair; Mesoblast; Novartis; Otsuka; Pfizer; Roche/Genentech; Sandoz; Takeda – IRC Chair.

Naval G. Daver, MD
Associate Professor
Director of the Leukemia Research Alliance Program
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant research support: Daiichi-Sankyo; Bristol Myers Squibb; Pfizer; Gilead; Sevier; Genentech; Astellas; AbbVie; ImmunoGen; Amgen; Trillium; Hanmi Pharmaceutical; Trovagene; FATE Therapeutics; Novimmune; Glycomimetics; Consultant: Daiichi-Sankyo; Bristol Myers Squibb; Pfizer; Gilead Sciences; Sevier; Genentech; Astellas; AbbVie; ImmunoGen; Amgen; Trillium; Arog Pharmaceuticals; Novartis; Jazz; Celgene; Syndax; Shattuck Labs; Agios.

Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research support: AbbVie; Agios/Servier Pharmaceuticals; BMS; Consultant: Pfizer; Trillium; AbbVie; Kura Oncology; Blueprint Medicines; Genentech, Novartis; Trovagene; Daiichi Sankyo; Novartis; Agios/Servier Pharmaceuticals; BMS; MorphoSys; Kite Pharma; Foghorn Therapeutics; Takeda; Amgen; Seattle Genetics; NewLink Genetics; Forty Seven; Ipsen.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.